Back to Results

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd. is a NASDAQ-listed common stock of a clinical-stage biotechnology company based in Ness Ziona, Israel. Through its subsidiaries, the company focuses on macrophage reprogramming immunotherapy and is developing AllocetraTM, a cell therapy intended to help restore macrophage homeostasis. Its pipeline includes an intra-articular AllocetraTM program for knee osteoarthritis, which is in a phase 1/2 trial, an intra-articular osteoarthritis program for the temporomandibular joint (TMJ), and Allocetra-OTS for adult sepsis patients with organ failure, which is in phase 2. The company was founded in 2005 and changed its name from Enlivex Therapeutics Ltd. to Enlivex Ltd. in February 2026.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ENLV
$1.02
58.3% Upside
Bargain
$80 12,283.9% Upside
Not available
Bargain
Good
0.0%
December 7, 2026
11.303 M
6.182 M
5.0%
30.4%
14.8
-0.8%
Valuation • Fair Value

Enlivex Therapeutics Ltd (NASDAQ-ENLV) Fair Value by Valuation Model

Review the available estimates for Enlivex Therapeutics Ltd (NASDAQ-ENLV), including Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.02

Estimated upside of 58.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$784.02

Classic Ben Graham valuation formula reference.

Comps Fair Value

$1.02

Comparable-company valuation reference.

Analyst Price Target

$80 12,283.9% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 5 available valuation references for Enlivex Therapeutics Ltd (NASDAQ-ENLV) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-14.668 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Enlivex Therapeutics Ltd (NASDAQ-ENLV) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Altman Z-Score

14.8

Relatively strong balance-sheet zone.

FCF / Net Income

-0.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Enlivex Therapeutics Ltd (NASDAQ-ENLV). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 7, 2026

Days to Earnings

76

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Enlivex Therapeutics Ltd (NASDAQ-ENLV), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Enlivex Therapeutics Ltd (NASDAQ-ENLV) Stock Forecast & Technical Outlook

Review Enlivex Therapeutics Ltd (NASDAQ-ENLV) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Enlivex Therapeutics Ltd (NASDAQ-ENLV) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Enlivex Therapeutics Ltd (NASDAQ-ENLV) Stock FAQ

Data-supported answers about Enlivex Therapeutics Ltd (NASDAQ-ENLV), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.02
Estimated upside 58.3%
Valuation Rating
Undervalued
Estimated upside of 58.3%
Analyst Target
$80 12,283.9% Upside
Data is currently unavailable
Financial Health
Good
Current financial-health read

The current fair value estimate for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is $1.02. This implies an estimated upside of 58.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 58.3% versus the current market price.

The available analyst price target for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is $80 12,283.9% Upside.

The current financial health read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is December 7, 2026.

The latest available data indicates no current dividend yield for Enlivex Therapeutics Ltd (NASDAQ-ENLV).

The current market capitalization listed for Enlivex Therapeutics Ltd is 11.303 M.

The current enterprise value listed for Enlivex Therapeutics Ltd is 6.182 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Enlivex Therapeutics Ltd is NASDAQ-ENLV, and the stock is listed on NASDAQ.

Enlivex Therapeutics Ltd (NASDAQ-ENLV) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Enlivex Therapeutics Ltd is 5.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Enlivex Therapeutics Ltd is 30.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B